In the 21st century investor’s toolkit, there are dozens of indicators shareholders can use to track Mr. Market. Two of the most under-the-radar are hedge fund and insider trading activity.
Earlier this month, Baxter International Inc. (NYSE:BAX) reported that the clinical trials for the treatment of Alzheimer’s disease (Gammagard) had failed.
Take one look at the returns from biotech darlings Celgene Corporation (NASDAQ:CELG), Biogen Idec Inc. (NASDAQ:BIIB), and Gilead Sciences, Inc. (NASDAQ:GILD) over the past year.
Hi-Tech Pharmacal Co. (NASDAQ:HITK) was in 11 hedge funds' portfolio at the end of December. HITK investors should be aware of an increase in hedge fund interest in recent months.
Despite its name, Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) has been losing steam since the end of 2011 with revenue falling 97% in the last nine months.